CEL-SCI Corporation announced on March 24, 2025, that new data from its prior Phase 3 study of Multikine was published in the peer-reviewed journal Pathology and Oncology Research. The article, 'Neoadjuvant Leukocyte Interleukin Injection Immunotherapy Improves Overall Survival in Low-risk Locally Advanced Head and Neck Squamous Cell Carcinoma -The IT-MATTERS Study,' included a comprehensive presentation of results.
The new, previously unpublished findings highlighted significant improvements in patient quality of life. Treatment with Multikine resulted in up to a 95% improvement in quality of life for head and neck cancer patients.
Specifically, complete responders to Multikine treatment reported 100% improvement on 60% of quality of life measures, including reduction in pain, improved ability to eat, drink, and swallow, and enhanced emotional wellbeing. Additionally, 89.4% of partial responders reported improved quality of life measures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.